BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32247769)

  • 1. Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules.
    Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
    J Am Soc Cytopathol; 2020; 9(4):232-241. PubMed ID: 32247769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplatform molecular test performance in indeterminate thyroid nodules.
    Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
    Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
    Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
    Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
    Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
    Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules.
    Jackson S; Kumar G; Banizs AB; Toney N; Silverman JF; Narick CM; Finkelstein SD
    Diagn Cytopathol; 2020 Jan; 48(1):43-52. PubMed ID: 31675178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of combined mutation analysis and microRNA classification in reclassifying cancer risk of cytologically indeterminate thyroid nodules.
    Banizs AB; Silverman JF
    Diagn Cytopathol; 2019 Apr; 47(4):268-274. PubMed ID: 30565896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
    Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of testing for mutations and microRNAs in thyroid nodules.
    Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
    Diagn Cytopathol; 2019 Aug; 47(8):758-764. PubMed ID: 31013001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules.
    Wu JX; Young S; Hung ML; Li N; Yang SE; Cheung DS; Yeh MW; Livhits MJ
    Thyroid; 2016 Jul; 26(7):916-22. PubMed ID: 27161519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?
    Lupo M; Guttler R; Geck Z; Tonozzi TR; Kammesheidt A; Braunstein GD
    Endocr Pract; 2018 May; 24(5):453-459. PubMed ID: 29498908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.
    Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED
    PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
    Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
    Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
    Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
    Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.